PointState Capital’s Sarepta Therapeutics SRPT Stock Holding History

PointState Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-198,900	Closed	-$26.3M	–	181
2018 Q2	$26.3M	Buy	+198,900	New	+$18.8M	0.3%	66
2018 Q1	–	Sell	-485,400	Closed	-$27M	–	200
2017 Q4	$27M	Buy	485,400 +84,400	+21%	+$4.47M	0.26%	68
2017 Q3	$18.2M	Sell	401,000 -230,922	-37%	-$9.23M	0.15%	87
2017 Q2	$21.3M	Sell	631,922 -6,978	-1%	-$227K	0.23%	67
2017 Q1	$18.9M	Buy	+638,900	New	+$19.8M	0.2%	74
2016 Q4	–	Sell	-270,000	Closed	-$16.6M	–	158
2016 Q3	$16.6M	Buy	270,000 +120,000	+80%	+$3.63M	0.17%	80
2016 Q2	$2.86M	Sell	150,000 -750,000	-83%	-$13.9M	0.06%	81
2016 Q1	$17.6M	Buy	900,000 +225,000	+33%	+$3.93M	0.47%	32
2015 Q4	$26M	Buy	675,000 +275,000	+69%	+$8.92M	0.66%	29
2015 Q3	$12.8M	Sell	400,000 -175,000	-30%	-$5.94M	0.36%	46
2015 Q2	$17.5M	Sell	575,000 -175,000	-23%	-$3.58M	0.2%	72
2015 Q1	$9.96M	Buy	750,000 +500,000	+200%	+$6.66M	0.13%	80
2014 Q4	$3.62M	Sell	250,000 -475,000	-66%	-$8.04M	0.06%	95
2014 Q3	$15.3M	Sell	725,000 -75,000	-9%	-$1.69M	0.28%	54
2014 Q2	$23.8M	Buy	800,000 +200,000	+33%	+$6.32M	0.3%	54
2014 Q1	$14.4M	Buy	+600,000	New	+$15.3M	0.23%	65
2013 Q4	–	Sell	-485,000	Closed	-$22.9M	–	174
2013 Q3	$22.9M	Buy	+485,000	New	+$18.7M	0.39%	55

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PointState Capital's SRPT Position: Q3 2018 in Review

PointState Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 198,900 shares — an estimated $26.3M sold.

PointState Capital first reported a position in SRPT in Q3 2013 and held it in 17 quarters. The position peaked at $27M in Q4 2017. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

PointState Capital reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
PointState Capital sold 198,900 Sarepta Therapeutics shares in Q3 2018, an estimated $26.3M.
PointState Capital first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 17 quarters.
PointState Capital's Sarepta Therapeutics position peaked at $27M in Q4 2017.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.